LY96 and atherosclerosis: Myeloid differentiation factor 2 (MD2) has been shown to be responsible for TLR4 activation and inflammation by directly binding to ox-LDL, which triggers the formation of the MD2/TLR4 complex and the proinflammatory TLR4-MyD88-NFκB cascade, opening a perspective for potential new therapeutic options for the treatment of atherosclerosis [70].